Follow sourced scientific, clinical, partnership, capacity, and financial developments. Factual summaries and business interpretations are presented separately.
Research runs each weekday at 8 a.m. Eastern Time. Channels update when qualifying developments are found. Editorial standards · RSS ↗
NGK announced development of a ceramic-membrane device for lipid nanoparticle manufacturing. The concept adjusts membrane area and porosity to retain a common mixing principle across processing scales, addressing quality changes that can occur when manufacturers switch mixing technologies. NGK reported encouraging evaluation results, but the device remains under development; commercial-scale GMP validation was not established in the announcement.
Antibody-coated nanoparticles targeted TREM2-expressing tumor-associated macrophages and combined CXCL9-encoding mRNA with a Toll-like receptor agonist. The approach remodeled the tumor immune environment and increased cytotoxic T-cell infiltration and activity. Additional checkpoint blockade strengthened immune responses in experimental models. This is a targeted delivery and combination-immunotherapy proof of concept, rather than evidence of efficacy in patients.
Ethris signed a €30 million financing agreement with the European Investment Bank under HERA Invest to support respiratory mRNA medicines. Its development platform pairs stabilized mRNA with lipid nanoparticles designed for local respiratory delivery, with programs spanning respiratory disease and mucosal vaccines. The announcement describes bank financing, not an equity round or an unconditional grant, and does not establish clinical success.
Using yeast RNA as a model payload, researchers evaluated atomization, freezing, drying temperature, and annealing during spray-freeze drying of RNA-LNPs. Powder diffraction, microscopy, and solid-state NMR supported characterization. Sucrose outperformed trehalose in the tested systems, and annealing improved stability. Because the payload was model RNA, these findings do not directly establish therapeutic mRNA expression potency or clinical-product stability.
Mote Therapeutics and Axelyf announced a cross-license combining Axelyf lipid nanoparticles with Mote’s CD8 T-cell-targeting binder. The companies intend to let third-party developers access the combined delivery technology through a single license while supplying their own nucleic acid payloads. Their approach uses mixing and noncovalent attachment. Financial terms were undisclosed, and clinical benefit was not established by the announcement.
The study introduces an ionizable lipid with two apparent ionization transitions that persist after nanoparticle formulation. Following intravenous administration, the particles favored pulmonary mRNA expression and improved outcomes in an experimental acute lung inflammation model. Simulations linked protonation states to membrane interactions. The work provides a mechanistic design hypothesis, with selectivity and tolerability established only in the tested preclinical settings.
Quantoom, a technology partner, reported Anvisa authorization for clinical testing of a COVID-19 booster developed on Bio-Manguinhos/Fiocruz’s Brazilian mRNA platform. Preclinical, toxicology, and scale-up work preceded the authorization. Phase 1 recruitment is planned for the first quarter of 2027, subject to ethics approval. This is permission to conduct a trial, not marketing authorization or evidence of human vaccine efficacy.
Beam presented updated open-label Phase 1/2 data for BEAM-302, an LNP-delivered in vivo base-editing treatment for alpha-1 antitrypsin deficiency. Follow-up extended to 18 months after one dose, with increased functional AAT and reduced mutant Z-AAT and circulating polymers. Dosing is underway in a pivotal cohort. These biomarker findings do not yet establish controlled evidence of improved lung or liver clinical outcomes.
Intellia announced FDA acceptance of its biologics license application for lonvoguran ziclumeran, or lonvo-z, in hereditary angioedema, with Priority Review and a March 10, 2027 target action date. The investigational treatment uses LNP-delivered CRISPR components for in vivo editing. Application acceptance advances the regulatory process but is not marketing approval and does not guarantee a favorable decision.
International journal of biological macromolecules
An injectable hydrogel co-delivered hyaluronidase and light-responsive nanoparticles carrying IL-12 and GM-CSF mRNAs. The design combined stromal remodeling, local retention, and photoactivated intracellular delivery. In a postoperative mouse breast-cancer model, treatment reduced recurrence and altered local and systemic immune responses. The multiple-component system remains experimental, with light access, long-term safety, and clinical feasibility requiring further work.
Proceedings of the National Academy of Sciences of the United States of America
Investigators combined mRNAs encoding an EpCAM-directed T-cell engager, IL-12, and GM-CSF through intratumoral nanoparticle administration. In partially humanized mouse xenograft experiments, the combination altered immune activity in both injected and uninjected tumors and inhibited tumor growth. The study supports localized production of several immune proteins, while the model cannot establish safety or effectiveness across human cancers.
Typewriter Therapeutics emerged from stealth with $56 million in Series A financing led by AN Venture Partners and RA Capital. Its platform uses LNP-delivered RNA, including mRNA encoding an R2 protein, to pursue targeted insertion of therapeutic genes. Initial priorities include in vivo CAR T and genetic liver disease. The funding announcement does not establish human safety, durability, or clinical benefit.
Continue your research
Explore company filters, side-by-side comparisons, private bookmarks, and member discussions.
